We studied the conversion of methotrexate to poly-'y-glutamyl derivatives by cultured human breast cancer cells. After incubation with 2 gM [3',5',9-3H] MM [3', 5', MTX in medium supplemented with 10MuM thymidine and 10MuM deoxyinosine. This medium allowed cell proliferation to proceed unperturbed as determined by cell counting and incorporation of [3H]thymidine. After the incubation period, medium was aspirated from the flasks and the cells were washed once with ice-cold phosphate-buffered normal saline, pH 7.4. Cells were scraped off the flask surface with a rubber policeman and, after two additional washes in ice-cold phosphate-buffered saline, were resuspended in 5 ml of 10 mM sodium ascorbate (pH 7.0) and boiled for 10 min. Cellular debris was pelleted by centrifugation at 10,000 X g for 15 min. The supernatant was decanted and saved for analysis of total intracellular MTX and derivatives and the cell pellet was resuspended in 5 ml of ice-cold phosphate-buffered saline and recentrifuged. The two supernatants were then pooled, lyophilized, and resuspended in 1 ml of double distilled H20 before being applied to a 1 X 50 cm Sephadex G-15 column equilibrated with 0.1 M NH4HCO3, pH 8.6 (2, 3) . The void volume of this column was 13 ml as determined by elution of dextran blue. Synthetic MTX+G1 and Abbreviations: MTX, 4-amino-NI0-methylpteroylglutamic acid (methotrexate); MTX+G1, 4-amino-NI0-methylpteroylglutamyl-,y-glutamic acid; MTX+G2, 4-amino-NI0-methylpteroylglutamyl-'y-glutamyl-'y-glutamic acid; DHFR, dihydrofolate reductase.
Methotrexate (MTX) is an important antineoplastic agent in the treatment of acute lymphoblastic leukemia, choriocarcinoma, osteogenic sarcoma, and breast cancer. Its cytotoxic action has been attributed to inhibition of dihydrofolate reductase (DHFR; tetrahydrofolate dehydrogenase; 5,6,7,8-tetrahydrofolate:NADP+ oxidoreductase, EC 1.5.1.3), thereby depriving the cell of reduced folate cofactors necessary for thymidylate and purine biosynthesis. Recently, poly-'y-glutamyl derivatives of MTX have been found in a number of animal and human tissues, including L1210 murine leukemia (1), rat hepatocytes (2), cultured rat hepatoma cells (3) , and cultured human fibroblasts (4) . These derivatives effectively inhibit the growth of L1210 murine leukemia in vitro and in vivo, and act as stoichiometric inhibitors of DHFR under appropriate cell-free conditions (1, 5) . However, whether intracellular MTX polyglutamates function primarily as storage forms of MTX or as biologically active antifolates has not been determined. This paper will present the results of studies showing that polyglutamate derivatives of MTX are rapidly synthesized by human breast cancer cells and, over time, become the predominant drug form bound to DHFR in these cells.
MATERIALS AND This medium allowed cell proliferation to proceed unperturbed as determined by cell counting and incorporation of [3H]thymidine. After the incubation period, medium was aspirated from the flasks and the cells were washed once with ice-cold phosphate-buffered normal saline, pH 7.4. Cells were scraped off the flask surface with a rubber policeman and, after two additional washes in ice-cold phosphate-buffered saline, were resuspended in 5 ml of 10 mM sodium ascorbate (pH 7.0) and boiled for 10 min. Cellular debris was pelleted by centrifugation at 10,000 X g for 15 min. The supernatant was decanted and saved for analysis of total intracellular MTX and derivatives and the cell pellet was resuspended in 5 ml of ice-cold phosphate-buffered saline and recentrifuged. The two supernatants were then pooled, lyophilized, and resuspended in 1 ml of double distilled H20 before being applied to a 1 X 50 cm Sephadex G-15 column equilibrated with 0.1 M NH4HCO3, pH 8.6 (2, 3) . The void volume of this column was 13 ml as determined by elution of dextran blue. Synthetic MTX+G1 and Abbreviations: MTX, 4-amino-NI0-methylpteroylglutamic acid (methotrexate); MTX+G1, 4-amino-NI0-methylpteroylglutamyl-,y-glutamic acid; MTX+G2, 4-amino-NI0-methylpteroylglutamyl-'y-glutamyl-'y-glutamic acid; DHFR, dihydrofolate reductase.
* To whom reprint requests should be addressed at: Building 10 (Fig. 1) . After a 1-hr incubation with MTX, the cytosol of MCF-7 cells was found to contain a primary peak of latemigrating radioactivity corresponding to authentic MTX, as well as a second small peak at tubes [15] [16] [17] [18] , the elution position of authentic MTX+G1. With continued incubation, the peak in tubes 15-18 became more prominent, and a third peak of radioactivity appeared in tubes 11-13, corresponding to the elution of authentic MTX+G2. By 24 hr the peak in tubes [11] [12] [13] comprised 70+ 3% of total intracellular radioactivity. These experiments indicated that, with prolonged incubation, human breast cancer cells convert MTX to higher molecular weight forms that comigrate with synthetic MTX polyglutamates.
The identity of the radioactive material in tubes [11] [12] [13] (Fig. 3A) and that corresponded to a Mr of 19,800 (Fig. 3B) . Radioactivity was not found associated with any other protein-containing column fractions. Disruption of the MTX-DHFR complex by boiling followed by repeat chromatography on Sephadex G-15 confirmed that greater than 75% of enzyme-bound MTX existed as polyglutamate derivatives (Fig. 3C) .
DISCUSSION
These experiments clearly show that human breast cancer cells rapidly and quantitatively convert MTX to polyglutamate forms during in vitro incubation. We have further shown that these polyglutamates bind to intracellular DHFR, and during extended periods of incubation become the predominant form of the drug bound to the enzyme. These findings, when considered with earlier studies of polyglutamate formation in murine tumor cells (1) and human fibroblasts (4), require a reappraisal of present concepts of MTX action.
Despite the high affinity of MTX for its target enzyme, much experimental evidence indicates that free intracellular MTX, in excess of intracellular levels of DHFR, is required to maintain inhibition of tetrahydrofolate synthesis (11) . In vio studies of MTX effects on normal gastrointestinal mucosa and bone marrow disclosed a threshold concentration of free drug required for inhibition of DNA synthesis in these tissues, with resumption of DNA synthesis in the presence of subthreshold concentrations of the MTX (12) . From these results it was concluded that a minimum concentration of free intracellular drug, characteristic for individual tissues, was necessary to maintain inhibition of DHFR. According to this concept, as MTX is cleared from the extracellular space, free intracellular drug will leave the cell and DNA synthesis will resume.
However, because the intracellular polyglutamate derivatives of natural folates and of MTX may not easily exit from the cell, they may be selectively retained in the absence of extracellular drug, thereby producing sustained inhibition of tetrahydrofolate synthesis. Indeed, Rosenblatt et al. (13) of DNA synthesis, which persists in the absence of extracellular drug. Thus, the present studies raise the possibility that the therapeutic response to MTX may be influenced by the ability of human tumor cells to form polyglutamates. The finding of MTX polyglutamates bound to DHFR indicates that these compounds, like folate polyglutamates (14) , function as biologically active enzyme inhibitors within the cell. Whitehead and Rosenblatt (15) have demonstrated that enzyme-bound MTX is not a substrate for polyglutamate synthesis. Thus, it appears likely that, as polyglutamates become the predominant form of free intracellular drug, a progressive replacement of parent compound by polyglutamates takes place at the enzyme binding site. Other experiments have indicated that the binding of MTX to DHFR is indeed reversible in intact cells (16) .
It appears then that the duration of the MTX effect in a given cell may be related to the extent of MTX polyglutamate synthesis and to the interactions of polyglutamates, MTX, and dihydrofolate at the enzyme binding site. In view of the present findings, it is now necessary to consider the possible role of MTX polyglutamate formation as a determinant of the cytotoxicity of MTX in human solid tumors. In particular, because MTX polyglutamate synthesis appears to increase as the dose of MTX is increased (4), and may vary considerably among various tissues (2), our findings help to explain the efficacy of regimens employing high-dose MTX exposure in the treatment of slowly growing solid tumors in man.
